The study by [@bib2] is an important work correlating prostate cancer death with the new 5 Grade Group system for prostate cancer. The novel Grade Group system was first proposed by the group from Johns Hopkins Hospital in 2013 ([@bib5]) and subsequently validated with a multi-institutional study by [@bib3] of over 20 000 men treated by radical prostatectomy and over 5000 men who underwent radiation therapy using biochemical recurrence as the end point.

The study by [@bib2] is the first to demonstrate that the 5 Grade Groups also correlate well with death due to prostate cancer, further validating the veracity of the new grading system. As noted by the authors, there are inherent weaknesses in the Transatlantic Prostate Group cohort used in the Berney *et al* study, as cases were included from as far back as 1990, when diagnosis and treatment of prostate cancer was very different than current practice. For example, sextant core biopsy was the most common biopsy technique used in the study by [@bib2], which is now recognised as suboptimal sampling of the prostate. However, the advantage of using these older cases is that there is sufficient follow-up that the study could assess death from prostate cancer.

This study also evaluates the controversial issue of whether the extra effort of calculating average grade on biopsy when there are multiple different cores with different grades adds significantly to predict prognosis as opposed to using the highest grade. In the United States, the typical practice is to assign a grade to each involved core and leave it up to the clinician to determine the grade used for treatment and prognosis, typically the core with the highest grade. The highest grade on a given core has been used for generating popular predictive and prognostic tools, such as the Kattan nomograms and the Partin tables. However, some pathologists in other countries have advocated for adding all the positive cores together as if it was one long core to determine the 'average\' or 'global\' Gleason score for the case. A more complicated and subjective variation on 'average\' Gleason score has been proposed by some pathologists where there they average together only some of the positive cores together based on their location and grade in an attempt to determine which is the dominant tumour nodule grade ([@bib1]). It is my practice to give the individual core grades and leave it up to the clinician to determine the grade for treatment and prognosis. It may be the highest grade on a given core or the clinician may have information on the dominant tumour location by multiparametric MRI and targeted biopsies, which could be factored in for determining the dominant tumour nodule grade. The pathologist does not always have access to the results of imaging procedures. The study by [@bib2] demonstrates that using the worst grade in a case, as opposed to the 'average\' grade, resulted in greater separation of Grade Groups 3 and 4. The worst grade was also used in both the initial and validating studies of Grade Groups ([@bib5]; [@bib3]), which showed significant differences in biochemical recurrence between Grade Groups 3 and 4.

[@bib2] add to the growing body of literature on the validity of the new simplified Grade Group system for prostate cancer. There are several advantages of the new system. First, it is a more accurate grade stratification than current applications of the Gleason system. The second major benefit of the new grading system is it is simple and intuitive, ranging from 1 to 5 as opposed to the current application of the Gleason system which in practice ranges from 6 to 10, and includes 7 that is separated into 3+4=7 and 4+3=7. The new grading system and its terminology 'Grade Groups 1--5\' were also adopted by the 2016 Edition of the World Health Organization of the Pathology and Genetics: Tumours of the Urinary System and Male Genital Organs. For the foreseeable future to ease the transition to the new grading system, it was agreed upon that both the Gleason grade and the Grade Groups would be included in pathology reports ([@bib4]).
